Publication

Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders: A PHAMOUS Study

Bruins, J., Pijnenborg, G. H. M., van den Heuvel, E. R., Visser, E., Corpeleijn, E., Bartels-Velthuis, A. A., Bruggeman, R. & Jörg, F., 2017, In : Journal of Clinical Psychiatry. 78, 8, p. 1117-1125 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders

    Final publisher's version, 425 KB, PDF document

DOI

Objective: People with psychotic disorders have an increased metabolic risk and a shortened life expectancy compared to the general population. Two large studies showed that metabolic disorders were untreated in a majority of the patients. Since then, guidelines have urged monitoring of metabolic health. This study examined the course of metabolic disorders over time in people with psychotic disorders and investigated current treatment rates.

Methods: A total of 1,259 patients with psychotic disorders, as defined by the DSM-IV, from 4 Dutch mental health institutions participated in 3 yearly assessments of the Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS) between 2006 and 2014. Patients' metabolic parameters were measured, and the use of pharmacologic treatment for hypertension (systolic blood pressure >= 140 mm Hg and/or diastolic blood pressure >= 90 mm Hg), dyslipidemia (5% = 2.5 mmol/L or SCORE risk >= 10% and LDL cholesterol level >= 1.8 mmol/L and/or triglycerides >= 2.3 mmol/L), and hyperglycemia (hemoglobin A(1c) concentration > 7% and/or fasting glucose concentration >= 7.2 mmol/L) was recorded.

Results: Prevalence of the metabolic syndrome, as defined by the National Cholesterol Education Program criteria, was > 50% at each assessment. On the basis of the European Society of Cardiology guidelines, pharmacotherapy for metabolic disorders was recommended for 52%-59% of the patients at each assessment. Treatment rates with antihypertensive (from 31% to 38%, P <.001) pharmacotherapy increased throughout the assessments. However, half of the patients were not treated for their metabolic risk factors while being monitored for 3 years or longer. Older patients were more likely to receive treatment, and patients who received treatment had lower blood pressure and lower cholesterol and triglyceride concentrations than patients not receiving the recommended treatment.

Conclusions: Metabolic risk factors are still seriously undertreated in people with psychotic disorders. Better adherence to and better implementation of guidelines about monitoring and treating metabolic disorders in psychiatry are crucial. (C) Copyright 2017 Physicians Postgraduate Press, Inc.

Original languageEnglish
Pages (from-to)1117-1125
Number of pages11
JournalJournal of Clinical Psychiatry
Volume78
Issue number8
Early online date11-Apr-2017
Publication statusPublished - 2017

    Keywords

  • SCHIZOPHRENIA SPECTRUM DISORDERS, SEVERE MENTAL-ILLNESS, CARDIOVASCULAR-DISEASE, ARTERIAL-HYPERTENSION, PHYSICAL HEALTH, BASE-LINE, CARDIOMETABOLIC RISK, PRACTICE GUIDELINES, CLINICAL-PRACTICE, TASK-FORCE

ID: 41412462